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(n = 356) received combined treatment (AB + 5ARI; 
AB + HESr; others). At 6 months, improvements in QoL 
were similar across the different medical treatment (MT) 
groups, both for monotherapy (AB: mean improvement 
[SD] of 2.4 points [2.4]; PT: 1.9 [2.4]; 5ARI: 2.5 [2.3]) 
and combined therapy (AB + 5ARI: 3.1 [2.9]; AB + PT: 
3.1 [2.5]). There were no clinically significant differences 
between MT groups and all showed significant improve-
ment over WW (p < 0.05). HESr showed similar efficacy 
to AB and 5ARI both as monotherapy and in combination 
with AB. Results on the IPSS were similar.
Conclusions Improvements in QoL and symptoms were 
equivalent across the medical treatments most widely used 
in real-life practice to manage patients with moderate or 
severe LUTS. HESr showed an equivalent efficacy to AB 
and 5ARI with fewer side effects.
Keywords LUTS · BPH · Quality of life · Real-life 
practice · BII · IPSS
Abstract 
Purpose To evaluate change in quality of life (QoL) and 
symptoms in patients with lower urinary tract symptoms/
benign prostatic hyperplasia (LUTS/BPH) in conditions of 
current clinical practice.
Methods Prospective, longitudinal, multicenter open-
label study was carried out in urology outpatient clinics. 
Patients were ≥40 years of age with an International Pros-
tate Symptom Score (IPSS) score ≥8. QoL and symptoms 
were measured at baseline and 6 months using the Benign 
Prostatic Hyperplasia Impact Index (BII) and the IPSS.
Results 1713 patients were included for analysis. Mean 
(SD) IPSS and BII scores at baseline were 16.8 (5.4) and 
6.8 (2.6), respectively. 8.9 % (n = 153) of study partici-
pants did not receive treatment (watchful waiting, WW), 
70.3 % (n = 1204) were prescribed monotherapy (alpha-
adrenergic blockers [AB]; phytotherapy [PT, of which 
95.2 % was the hexanic extract of Serenoa repens, HESr]; 
or 5-alpha-reductase inhibitors [5ARI]), and 20.8 % 
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Introduction
Benign prostatic hyperplasia (BPH) is a common condi-
tion in older men that can often result in lower urinary tract 
symptoms (LUTS) [1]. LUTS associated with BPH (LUTS/
BPH) can have a significant negative impact on patients’ 
quality of life (QoL) [2–4] as can certain treatments for the 
condition, some of which cause sexual dysfunction [5, 6].
Although the efficacy and safety of medical treatments 
such as alpha-adrenergic blockers, 5-alpha-reductase inhib-
itors, phytotherapy, combination therapy, antimuscarinic 
agents and phosphodiesterase type 5 inhibitors have been 
assessed in numerous clinical trials [7], fewer studies have 
evaluated those treatments in current clinical practice. Fur-
thermore, observational studies to date have tended to focus 
on individual therapies, making it difficult to compare 
outcomes for different treatments under real-world condi-
tions [8, 9]. There is therefore a need for large-scale studies 
which evaluate the range of treatments used to treat LUTS/
BPH in daily practice and which allow results to be com-
pared across treatments. Such studies are useful in that they 
provide complementary data to that obtained in controlled 
clinical trials, where patients, centers, and compliance may 
not be representative of broader clinical practice [10].
The Quality of Life in Benign Prostatic Hyperplasia 
(QUALIPROST) study was designed to assess change in 
the QoL of a large cohort of patients with moderate-to-
severe LUTS/BPH managed using therapeutic approaches 
typically found in real-world clinical practice. Quality of 
life was assessed using the BPH Impact Index (BII), an 
international, validated questionnaire, and a further objec-
tive was to investigate how changes in symptoms correlated 
with changes in QoL.
Subjects and Methods
Patients and study design
This was a longitudinal, prospective, observational, mul-
ticenter study to evaluate change in QoL in patients with 
moderate-to-severe LUTS/BPH managed in a urologi-
cal setting. The study was performed in centers through-
out Spain from September 2009 to June 2011. Quality of 
life and BPH symptoms were measured at baseline and at 
a 6-month follow-up visit. Patients were included if they 
were ≥40 years of age with a diagnosis of LUTS/BPH and 
an IPSS score of ≥8. Patients were excluded if they had 
received drug treatment for BPH in the 6 months prior to 
inclusion or if they had received any drug treatment with 
a known effect on BPH symptoms (such as diuretics, anti-
histamines, or tricyclic antidepressants) for any length of 
time in the 4 weeks prior to inclusion. Patients were also 
excluded if they had other urinary disorders (prostatitis, 
urinary incontinence, urethral strictures, or prostate cancer) 
or if they had previously undergone surgery of the lower 
urinary tract.
Study variables
The primary endpoint was change in QoL assessed using 
the validated Spanish version of the Benign Prostatic 
Hyperplasia Impact Index (BII), a self-administered ques-
tionnaire consisting of four questions measuring the impact 
of urinary symptoms on physical discomfort, worries about 
health, symptom bother, and interference with usual activi-
ties during the past month [11, 12]. Items are answered 
using a Likert scale, with four or five response options per 
item and scores range from 0 (best QoL) to 13 (worst QoL).
Symptoms of LUTS/BPH were evaluated using the vali-
dated Spanish version of the International Prostate Symp-
tom Score (IPSS) [13]. Scores on this instrument range from 
0 to 35 with a higher score indicating more severe symp-
toms and a change in IPSS score of ≥3.1 corresponding to 
a clinically meaningful change in patients’ global feeling 
of urination [14]. Both instruments were self-completed by 
patients at baseline and at the 6-month follow-up visit.
Sociodemographic data collected at baseline included 
age, weight, and height, the latter two being used to cal-
culate the body mass index (BMI). Clinical data collected 
included date of initiation of urinary symptoms, year of 
LUTS/BPH diagnosis, and severity of BPH according to 
IPSS score (moderate = 8–19, severe = 20–35). We also 
collected data on diagnostic tests (digital rectal examina-
tion, prostate volume, Qmax, urine analysis, serum analy-
sis, PSA), treatment received (yes/no, alpha-blockers, 
5-alpha-reductase inhibitors, phytotherapy, other), and co-
morbidities (high blood pressure, diabetes, dyslipidemia, 
or “other”), as well as treatment for co-morbidities. Side 
effects associated with treatment were recorded at the fol-
low-up visit, and treatment compliance was assessed using 
the validated Spanish version of the Haynes–Sackett ques-
tionnaire [15]. This questionnaire consists of two parts. In 
the first part, the patient is asked whether he has difficulty 
taking his medication. In the second part, those who have 
answered yes to the first question are asked about the tab-
lets they have taken in the previous month. Good adherence 
is considered to be achieved when the percentage of pills 
taken is between 80 and 110 % of the prescribed dose.
As this was a real-world study of patient management, 
investigators could prescribe any of the commercially 
available treatments according to their current practice. 
Based on treatment availability in Spain when the study 
was performed, several brands of alpha-blockers were pre-
scribed. Tamsulosin was the most frequently prescribed 
alpha-blocker (principally Omnic®, Urolosin® or generics, 
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at a recommended dose [RD] of 0.4 mg daily), followed 
by finasteride (principally Proscar® or generics at an RD of 
5 mg/day). Only one brand of the following treatments was 
available and approved and covered by the NHS: dutas-
teride (Avidart®; RD: 0.5 mg/24 h), P. africanum (Tebe-
tane compuesto®; RD: 60 mg/day), and hexanic extract of 
Serenoa repens (Permixon®; RD: 320 mg daily).
Sample size
Sample size was calculated to detect a difference of 0.2 
points in the BII overall score between baseline and follow-
up with a statistical power of 80 % and a significance level 
of 0.05 using the Student t test for paired data. Assuming a 
loss to follow-up of 10 %, we calculated that a total sample 
size of 1638 patients would be required.
Statistical analysis
Change over time within groups and differences in the size 
of change on the two primary outcome measures between 
groups receiving different medical treatments, or patients on 
watchful waiting, were assessed using parametric (Student 
t test) or nonparametric tests (Mann–Whitney) as appropri-
ate. Analyses were carried out using per protocol (PP) and 
intent-to-treat (ITT) samples. All analyses were carried out 
for the overall study population and by subgroups catego-
rized by medical treatment. Furthermore, a subset analysis 
was carried out in which patients were categorized by their 
baseline IPSS scores as moderate-low (8–13 points), mod-
erate-high (14–19), and severe (≥20). As no differences in 
efficacy have been observed between the components of the 
therapeutic families of alpha-blockers and 5-alpha-reductase 
inhibitors, for the purposes of analysis in this study they 
were grouped together [16–18]. The correlation between 
change in symptoms as measured on the IPSS and change 
in QoL assessed using the BII overall score, was evaluated 
using Pearson’s correlation coefficient.
Comparisons of effectiveness between different medi-
cal treatments, and between medical treatment and watch-
ful waiting, were carried out only after confirming that 
there were no statistically significant differences in base-
line characteristics between the groups receiving different 
treatments. If this was not the case, results were offered in 
descriptive form. In all comparisons, results were consid-
ered statistically significant when p < 0.05. Statistical anal-
yses were carried out using SAS 9.3 statistical software.
Results
A total of 119 urologists participated in the study and a 
total of 1888 patients were recruited, of which 1713 were 
available for ITT analysis (Fig. 1). 6.5 % of patients were 
lost to follow-up. 11.1 % of patients included in the watch-
ful waiting group switched to another treatment before 
study end. The proportion of patients switching treatments 
was very similar in the different pharmacological treatment 
groups (mean of 4.1 % across the groups).
Table 1 shows the study population’s sociodemographic 
and clinical characteristics according to treatment regimen. 
The mean (SD) time from diagnosis of BPH was 1.3 (2.8) 
years. In terms of treatment, 8.9 % of the patients were 
in WW, 70.3 % received monotherapy, and 20.8 % com-
bined therapy. The number of patients initiating any type 
of treatment is shown in Table 1. Tamsulosin was the most 
frequently prescribed alpha-blocker (88.7 % of all alpha-
blockers), dutasteride the most frequently prescribed 5ARI 
(53.2 % of all 5ARI), and hexanic extract of S. repens the 
most common phytotherapy (95.2 % of all phytotherapy).
Patients receiving phytotherapy tended to be slightly 
younger than patients in the other treatment groups. In 
terms of clinical characteristics, patients on watchful wait-
ing (WW) and those treated with phytotherapy tended 
to have slightly lower baseline prostate volume and IPSS 
scores, and higher Qmax.
Figures 2 and 3 show scores on the BII and IPSS, respec-
tively, at baseline and at 6 months, overall and according 
to LUTS treatment. Patients receiving combination therapy 
had higher mean baseline BII and IPSS scores than those 
treated with monotherapy or WW. All medical treatment 
categories showed a relevant improvement in BII and IPSS 
scores after 6 months. The smallest improvement was 
observed in the WW group, with a mean (SD) change of 
1.0 (2.2) and 2.5 (4.4) points on the BII and IPSS, respec-
tively, compared to mean (SD) change scores of 2.3 (2.5) 
and 5.0 (4.9) for the same outcomes in treated patients.
When comparing monotherapy treatment overall with 
WW in patients with a baseline IPSS score between 14 and 
19, a statistically significant mean (SD) improvement on 
IPSS score of 4.5 (3.7) was observed for monotherapy ver-
sus 3.0 (2.9) for WW (p < 0.006) and 2.2 (2.4) versus 1.1 
(2.0) on the BII (p < 0.004). The largest changes in symp-
toms and QoL were observed in patients with more severe 
baseline symptoms (Tables 2, 3).
When changes in BII and IPSS scores were compared 
across groups receiving different monotherapies, taking 
into account initial symptom severity, no statistically sig-
nificant differences were observed. In patients with moder-
ate-high (14–19) or severe (≥20) baseline IPSS, all medi-
cal treatment modalities achieved a reduction in symptom 
severity of at least 4 points on the IPSS, which would rep-
resent a clinically significant improvement.
In patients with a baseline IPSS of 14–19, there were 
no statistically significant differences in the magnitude of 
improvement in QoL between patients treated with AB, 
648 Int Urol Nephrol (2016) 48:645–656
1 3
5ARI, or HESr as monotherapy when results were com-
pared in two by two analyses. Likewise, in the same sub-
group of patients, there were no statistically significance 
differences between AB and HESr or between AB and 
5ARI in the magnitude of improvement on IPSS. Improve-
ments in QoL in all three medical treatment groups (AB, 
5ARI, HESr) were larger than those observed in the WW 
group, and all differences were significant (p < 0.05). 
Improvements in QoL and symptoms were similar in 
patients treated with AB + 5ARI or AB + HESr when 
baseline IPSS was taken into account, and no statistically 
significant differences were observed between these two 
groups.
In patients with more severe baseline symptoms 
(IPSS ≥ 20), improvements in QoL and IPSS scores were 
also similar between those treated with AB, 5ARI, or HESr 
and no statistically significant differences were observed 
between the groups in two by two comparisons of the treat-
ments as monotherapy. Similar results, i.e., no statistically 
significant differences in the magnitude of improvement 
Patients recruited into study and 
assessed for eligibility
(n=1888)
EXCLUDED FROM ITT ANALYSIS 
(n=175)*
• <40 years of age (n=1)
• Surgery, other urinary               
disorders (n=8)
• Prior drug treatment for BPH (n=132)
• No baseline BII or IPSS data (n=37)
Patients eligible for inclusion in 
ITT analysis
(n=1713)
EXCLUDED FROM PP ANALYSIS 
(n=201)*
• No BII or IPSS data at baseline or 6 
months (n=126)
• Did not continue the treatment at 6 
months (n=7)
• Did change to another treatment at 6 
months (n=80)
• Loss to follow-up             (n=112)
Patients eligible for inclusion in 
PP analysis
(n=1512)
Fig. 1  Flow diagram for patient inclusion in study. *Figures in indi-
vidual rows may not sum to overall n as patients could have more 
than one exclusion criteria. IPSS International Prostate Symptom 
Score, BII Benign Prostatic Hyperplasia Impact Index, ITT Intention 
to treat, PP Per protocol
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Fig. 2  Baseline and end of study scores on BII, overall and by treatment group (n patients). BII Benign Prostatic Hyperplasia Impact Index. WW 
watchful waiting, AB α- blockers, 5ARI 5α-reductase inhibitors, P. africanum Pygeum africanum, HESr hexanic extract of Serenoa repens
Fig. 3  Baseline and end of study scores on IPSS, overall and by treatment group (n patients). IPSS International Prostate Symptom Score. WW 
watchful waiting, AB α-blockers; 5ARI 5α-reductase inhibitors, P. africanum Pygeum africanum, HESr hexanic extract of Serenoa repens
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in QoL, were observed in the comparisons between 
AB + 5ARI and AB + HESr.
Changes on the IPSS and BII were highly correlated, 
with a coefficient of r = 0.66 in the study population 
overall (p < 0.0001). When analyzed by baseline symptom 
severity, correlations ranged from r = 0.60 (p < 0.0001) in 
the group with moderate baseline symptoms to r = 0.70 
(p < 0.0001) in the group with severe baseline symptoms. 
Table 2  Change scores on BII 
by treatment regimen according 
to baseline IPSS score
Groups with <25 patients were excluded from the analysis due to small sample size and a high degree of 
variability in results
Numbers in superscript indicate the results of statistical testing
If there is no superscript number, then it was not possible to test for significance due to differences in the 
mean IPSS baseline score
IPSS International Prostate Symptom Score, BII Benign Prostatic Hyperplasia Impact Index, AB α- block-
ers, 5ARI 5α-reductase inhibitors, HESr hexanic extract of Serenoa repens
1,2,3 Statistically significant difference observed at p < 0.05 between groups with the same superscript 
number
4,5,6,7,8,9,10 No statistically significant differences observed between groups with the same superscript num-
ber
Baseline IPSS (8–13) Baseline IPSS (14–19) Baseline IPSS (≥20)
n Mean  
change




Watchful waiting, mean (SD) 64 0.3 (1.7) 46 1.1 (2.0)1,2,3 –
Monotherapy, mean (SD)
 AB 87 1.7 (1.9) 171 2.5 (2.4)1,4 118 2.8 (2.6)7,8
 5ARI – 34 2.1 (2.0)2,4,5 45 3.0 (2.5)7,9
 HESr 269 1.2 (1.9) 256 2.0 (2.4)3,5 106 2.9 (3.1)8,9
Combination therapy, mean (SD)
 AB + 5ARI – 25 2.3 (2.5)6 58 3.7 (3.0)10
 AB + HESr 32 2.2 (2.5) 84 2.9 (2.4)6 86 3.7 (2.6)10
Table 3  Change scores on IPSS 
by treatment regimen according 
to baseline IPSS score
Groups with <25 patients were excluded from the analysis due to small sample size and a high degree of 
variability in results
Numbers in superscript indicate the results of statistical testing
If there is no superscript number, then it was not possible to test for significance due to differences in the 
mean IPSS baseline score
IPSS International Prostate Symptom Score, BII Benign Prostatic Hyperplasia Impact Index, AB α- block-
ers, 5ARI 5α-reductase inhibitors, HESr hexanic extract of Serenoa repens
1 Statistically significant difference observed at p < 0.05 between groups with the same superscript number
2,3,4,5,6,7,8,9,10 No statistically significant differences observed between groups with the same superscript 
number
Baseline IPSS (8–13) Baseline IPSS (14–19) Baseline IPSS 
(≥20)
n Mean  
change




Watchful waiting, mean (SD) 64 0.5 (3.1) 46 3.0 (2.9)1 –
Monotherapy, mean (SD)
 AB 87 2.4 (2.6) 171 4.6 (3.5)2,3 118 7.6 (4.7)5,6
 5ARI – 34 5.2 (4.4)3 45 9.0 (6.0)5,7
 HESr 269 1.7 (3.3) 256 4.2 (3.7)1,2 106 7.9 (5.3)6,7
Combination therapy, mean (SD)
 AB + 5ARI – 25 4.4 (4.6)4 58 9.8 (6.5)
 AB + HESr 32 2.8 (2.8) 84 5.0 (3.4)4 86 9.5 (5.1)
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A similar correlation was found between BII and ques-
tion 8 (QoL) of the IPSS, at r = 0.57 for the overall sam-
ple (p < 0.0001), and r = 0.53 (p < 0.0001), and r = 0.56 
(p < 0.0001) for the moderate, and severe baseline symp-
toms groups, respectively.
Table 4 shows the incidence of adverse effects (AE) 
overall and for the 5 most frequent reported AE. In patients 
receiving monotherapy, AB had the highest incidence of 
AE (16.3 %) and HESr the lowest (0.8 %); among com-
bination therapies, AB + 5ARI had the highest rate of AE 
(30.5 %). Proportionally, the most frequent AE were erec-
tile dysfunction and reduced libido. In terms of absolute 
numbers, retrograde ejaculation was the most common AE 
(31 patients in the AB group).
The PP analysis showed a similar pattern of results for 
all endpoints analyzed.
With respect to treatment compliance, approximately 
90 % of patients in each medical treatment group (both 
monotherapy and combination treatment) reported that 
they had no difficulty taking the medication. Among those 
reporting some type of difficulty, 90 % of patients men-
tioned that they were taking >80 % of the prescribed treat-
ment, except for 5ARI patients, who reported 80 %.
Discussion
This study has evaluated changes in symptoms and QoL 
in a large cohort of patients with LUTS/BPH managed 
in conditions of real-life practice. We observed signifi-
cant improvements in both symptoms and QoL in patients 
receiving any form of medical treatment. As could be 
expected, improvements were greater in patients with 
higher baseline IPSS scores and smaller in the WW group 
than in patients receiving any sort of medical treatment.
A relevant contribution of this study is that it assesses 
the effect on QoL of several medical treatments for LUTS/
BPH used in real-life practice by means of an internation-
ally recognized, validated questionnaire that is easy to use 
in regular clinical practice, whereas earlier studies tended 
to focus almost exclusively on symptoms [8, 18, 19] or on 
outcomes associated with a single drug [19, 20]. In the pre-
sent study, treatment regimens were chosen by participat-
ing urologists based on their current practice, and the distri-
bution of patients across different pharmacological options 
is in line with data published in a previous report [21].
All of the medical treatments studied were associated 
with improvements in both symptoms and QoL and the 
average improvement was similar to that observed in pre-
vious studies of different drug therapies using the BII and 
IPSS questionnaires [22–24]. Patients treated with hex-
anic extract of S. repens showed similar improvements in 
symptoms to those observed with AB or 5ARI monother-
apy, thereby confirming the results of earlier randomized 
clinical trials [23–27]. It was not possible to compare IPSS 
outcomes between 5ARI and HESr in the group of patients 
with a moderate baseline IPSS (14–19) because of differ-
ences in baseline mean IPSS values.
Earlier publications have suggested that extracts of S. 
repens appear to be no more effective than placebo [28–30]; 
nevertheless, while not recommended by the AUA BPH 
Guideline, they are considered as a treatment option [31] 
and have well-established mechanisms of action [32–35]. It 
is important to note that general conclusions about S. repens 
can mask the fact that not all S. repens extracts have the 
same potency, and that the latter appears to be dependent 
on extraction procedure. Indeed, current European LUTS/
BPH guidelines [36], while making no any recommendation 
on phytotherapy as a therapeutic group, do mention specific 
medications supported by clinical studies and a substantial 
Table 4  Incidence of all-cause adverse effects after 6 months of follow-up
AE adverse effects, BP blood pressure, AB α- blockers, 5ARI 5α-reductase inhibitors, P. africanum Pygeum africanum, HESr hexanic extract of 
Serenoa repens










 AB 424 69 (16.3) 31 (7.3) 19 (4.5) 3 (0.7) 4 (0.9) 10 (2.4)
 5ARI 106 15 (14.2) 0 2 (1.9) 10 (9.4) 9 (8.5) 0
 HESr 733 6 (0.8) 0 0 0 0 0
 P. africanum 34 1 (2.9) 0 0 0 0 0
Combination therapy, n (%)
 AB + 5ARI 105 32 (30.5) 10 (9.5) 8 (7.6) 16 (15.2) 16 (15.2) 4 (3.8)
 AB + HESr 234 33 (14.1) 12 (5.1) 12 (5.1) 7 (3.0) 2 (0.9) 6 (2.5)
 5ARI + HESr 29 5 (17.2) 0 1 (3.4) 3 (10.3) 3 (10.3) 0
 Other combinations 20 3 (15) 0 1 (5.0) 3 (15) 1 (5.0) 0
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weight of evidence regarding their efficacy. They also note 
that different brands of phytotherapy need to be assessed 
individually, as differences in their potency [36–39] mean 
that results from one brand cannot be extrapolated to another. 
In that sense, the results of clinical studies such as those cited 
above [28, 29] would only apply to the particular extract of 
S. repens used in those studies. The authors of the Cochrane 
Collaboration meta-analysis [30] came to a similar conclu-
sion when they stated “we do not know if the present conclu-
sions are generalizable to proprietary products of S. repens 
extracts, such as Permixon® or Prostagutt® forte.” A recent 
European Medicines Agency (EMA) report also concluded 
that only the hexanic extract of S. repens has sufficient evi-
dence to support its use as a well-established medicinal prod-
uct with recognized efficacy and acceptable safety [36].
As expected, adverse effects were lowest in patients 
treated with phytotherapy. On the other hand, almost 10 % of 
patients in the AB and 5ARI groups reported problems with 
sexual functioning, a proportion which is similar to previous 
reports [5, 40]. Specifically, treatment with alpha-blockers 
has been associated with a high incidence of ejaculatory dis-
order [41, 42], and a recent meta-analysis showed that ejacu-
latory dysfunction is significantly associated with the use of 
AB or 5ARI, with a threefold increase in risk for AB + 5ARI 
combination therapy compared with AB or 5ARI alone [43].
In the present 6-month study, combination therapy with 
AB + 5ARI and AB + HESr showed a similar level of 
improvement in BII score, though with a lower incidence 
of adverse effects for AB + HESr. The symptoms improve-
ment measured by the IPSS questionnaire was also similar 
for these combinations, and not statistically significant dif-
ferences were observed between the two therapeutic com-
binations in patients with a baseline IPSS score of 14–19. 
In patients with a baseline IPSS subgroup ≥20, though the 
improvement in symptoms was similar with both combina-
tions, it was not possible to statistically compare outcome 
on the IPSS because of differences in mean baseline IPSS 
values. Previous studies have reported a tendency to use 
AB in combination with phytotherapy [44–46], but this is 
the first time to our knowledge that the effects of this com-
bination on QoL and symptoms, and its tolerability, have 
been evaluated prospectively in real-life practice. Although 
improvement was equivalent between the two groups, the 
6-month follow-up period did not allow us to draw any 
conclusions about disease progression. Nevertheless, pro-
gression appears to be slow and relatively limited in LUTS/
BPH. Effectively, based on the MTOPS [47] and CombAT 
[48] trials, between 79 and 83 % of patients with moderate-
severe LUTS/BPH would not be expected to show clinical 
progression after 4 years. In that case, intensive medical 
treatment may not offer more benefit than other treatments 
and could lead to more side effects [47, 48] causing a nega-
tive impact on QoL. It would be of interest to investigate 
more precise LUTS/BPH progression markers to more reli-
ability identify patients who are likely to experience dis-
ease progression.
Finally, it is interesting to note that adherence in the 
present study was over 90 %, without major differences 
between the treatment groups in the present 6-months fol-
low-up study. A recent retrospective study using data from an 
administrative prescription database [49] reported an adher-
ence close to 65 % after 10 months in a broad population 
of patients receiving treatment for LUTS/BPH up to 8 years. 
However, the different methodologies used, different time 
periods, and the presence of other treatments in the analysis 
could explain the differences between the two studies.
The present study has some limitations. Data were 
obtained under conditions of real-life practice with no 
randomization or blinding; patients were therefore allo-
cated to a specific management approach based on clini-
cian judgment, which could lead to a selection bias. For 
example, patients treated with phytotherapy were younger 
and had less severe symptoms, which could explain some 
of the differences in outcomes because symptom relief and 
improvements in QoL are usually greater in patients with 
more severe symptoms [24]. This effect was minimized 
to some extent by grouping patients with similar baseline 
IPSS scores for analysis and confirming their comparability 
before analyzing the results. The relatively short follow-up 
period of six months could also be considered a limitation 
when studying a chronic disease. Nevertheless, it was not 
our intention to study disease progression and the study 
duration is in line with other recent studies, some of which 
used even shorter treatment periods [50, 51]. Finally, as this 
was an observational study in which we were interested 
in outcomes obtained under conditions of current clinical 
practice, there was no placebo arm. On the other hand, the 
inclusion of a watchful waiting group in this type of study 
can provide valuable information about the natural progres-
sion of the disease and what can be expected in patients 
who receive no treatment; in this case, the outcomes were 
notably better in all of the medical treatment groups than in 
the watchful waiting group.
Despite such limitations, real-world practice studies can 
contribute useful information on the outcomes associated 
with day-to-day patient management strategies and are a 
useful complement to clinical trials, the results of which do 
not always transfer to real-life practice [10]. In the present 
case, the large sample size also confers a high degree of 
precision and reliability on the results.
Conclusions
Improvements in QoL and IPSS scores were equivalent 
across the medical treatments most widely used in real-life 
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practice to manage patients with moderate or severe LUTS/
BPH, and all medical treatments studied were associ-
ated with considerably larger improvements in QoL and 
symptoms than WW. Hexanic extract of S. repens showed 
equivalent efficacy to AB and 5ARI without the side effects 
on sexual function associated with those treatments, and 
its combination with AB appears to have a similar level 
of efficacy as the combination treatment with AB + 5ARI 
in the median term. The results of this study add to the 
evidence pool on current treatments for LUTS/BPH and 
should help to further inform decision-making regard-
ing treatment. Such decision-making should also take into 
account the patient’s clinical condition and their risk–ben-
efit preferences.
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